Home
overview
Diabetes is the only non-infectious condition that is classified by WHO as an epidemic. With the increasingly sedentary lifestyle, high fat/high sugar diets and the ageing populations of the developed word, it has been estimated that over the next 12 years the number of diabetes sufferers will increase from 2.1% to 3% of the global population, with the most significant increases in Asia. A recent report in the Journal of Diabetic Medicine concluded that the number of people with diabetes will double to 220 million by the year 2010.

In our 5th annual conference, SMi will be looking once again to bring together the leading experts from the pharmaceutical industry to determine how much progress has been made in realising the potential for more efficacious therapies and diagnostics.

As current blockbusters approach their patent expiry, the conference will include presentations from the market leaders, specialist companies and renowned academics to talk about the latest innovations in diabetes treatment.

Benefit from industry presentations by:
· Dr Jacques Mizrahi, Director, Global Therapeutic Area Head, Vascular & Metabolic Diseases, F Hoffmann-La Roche
· Dr Michael Trautmann, Medical Advisor, Eli Lilly
· Dr Richard Carr, Scientific Vice President, New Antidiabetic Agents, Novo Nordisk
· Dr Smilinia Ristic, Global Head, Diabetes Clinical Research, Novartis
· Dr Michael Goldberg, Chairman & Chief Executive Officer, Emisphere Technologies
· Richard Thompson, President & Chief Executive Officer, Aradigm
· Dr Marianne Olholm Larson, Department Head, Pharmacology, Novo Nordisk
· Dr Christopher Price, President & Chief Executive Officer, Nobex
· Dr Andrew Young, Vice President & Senior Research Fellow, Amylin
· Dr Andrew Swick, Manager, Cardiovascular & Metabolic Diseases, Pfizer
· Dr Harold Van Wart, President & Chief Executive Officer, Metabolex
· Dr Cord Dohrmann, Chief Scientific Officer, DeveloGen

Key issues that will be addressed at this Conference include:
· BETA-CELLS: learn about Pax4, a marker of early beta-cell development that is required and sufficient for beta-cell regeneration
· EFFECTIVE GLUCOSE AND LIPID-LOWERING AGENTS: discuss the benefit of PPAR-gamma insulin sensitizers in diabetes treatment
· GLP-1 ANALOGUES: hear about exenatide and current studies on effects on glycemic control and weight control
· INHIBITORS: assess PDH kinase inhibitors as potential therapy for type II diabetes
· ORAL INSULINS: evaluate the conversion of liquid or dry insulin into a breathable medicine
· INDUSTRY LEADERS: network and discuss ideas with the leaders in the field

“Great update on emerging drugs”
Christen Anderson, Director, Metabolic Diseases, Mitokor (Attendee, SMi’s DIABETES 2002)

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Richard Carr

Dr Richard Carr, Scientific Vice President, New Antidiabetic Agents, Novo Nordisk

9:10 MARKET OVERVIEW

Carole Gleeson

Carole Gleeson, Analyst, Immune & Inflammatory Disorders, Decision Resources

  • Increasing prevalence
  • Unmet needs
  • Global variations (US, Europe, Japan)
  • Drugs on the market
  • Drugs in the pipeline
  • Market opportunities
    What developments are expected in the next 3-5 years?
  • 9:40 A NEW PARADIGM FOR POST PRANDIAL INSULIN RESISTANCE?

    Prof Wayne Lautt

    Prof Wayne Lautt, Department of Pharmacology & Therapeutics, Faculty of Medicine, University of Manitoba

  • The hepatic insulin sensitizing substance (HISS)hypothesis
  • The rapid insulin sensitivity test (RIST)
  • Meal induced HISS release
  • Cholinergic and nitridergic permissive control of HISS release
  • Therapeutic reversal of postprandial insulin resistance
  • 10:20 GENOMICS OF TYPE I AND II

    Dr Bentley Cheatham

    Dr Bentley Cheatham, Director, Metabolic Disease Research, Ribonomics

  • A novel approach for refining array analysis
  • Defining pathway information
  • Identification of novel drug targets
  • What are the goals for the future?
  • 11:00 Morning Coffee

    11:20 BETA-CELLS

    Dr Cord Dohrmann

    Dr Cord Dohrmann, Chief Scientific Officer, DeveloGen

  • Pax4: a marker of early beta-cell development that is required and sufficient for beta-cell regeneration
  • HTS for small molecule activators of Pax4 expression
  • Secreted factor screen for regulators of beta-cell
  • DG70: a kinase involved in the control of food intake and fat metabolism
  • DG70 transgenic mice closely mimic various aspects of obesity such increased food intake, increased fat storage (particularly in liver and adipose tissue) as well as insulin resistance
  • A hit series of DG70 inhibitors has been identified, potential lead is active in human adipocytes
  • 12:00 BETA-CELL REST

    Dr Richard Carr

    Dr Richard Carr, Scientific Vice President, New Antidiabetic Agents, Novo Nordisk

  • Pharmacology of ATP sensitive potassium channels
  • NN414: pharmacology and pre-clinical profile
  • Position of beta-cell rest in treatment of type II diabetes
  • 12:40 Networking Lunch

    13:40 THE GÖTTINGEN MINIPIG IN DIABETES RESEARCH

    Dr Marianne Olholm Larson

    Dr Marianne Olholm Larson, Department Head, Pharmacology, Novo Nordisk

  • The Göttingen minipig as a model of diabetes
  • Past achievements and current developments
  • Investigating different functional tests as predictors of beta-cell mass in the Göttingen minipig
  • Evaluation of beta-cell mass in vivo
  • 14:20 GLUCOCORTICOIDS, OBESITY AND DIABETES

    Dr Andrew Swick

    Dr Andrew Swick, Manager, Cardiovascular & Metabolic Diseases – Obesity, Pfizer

  • Glucocorticoid receptor antagonists
  • Tissue-specific regulation of glucocorticoids – 11âHSD
  • Leptin as a counter-regulatory hormone
  • 15:00 EFFECTIVE GLUCOSE AND LIPID-LOWERING AGENTS

    Dr Harold Van Wart

    Dr Harold Van Wart, President & Chief Executive Officer, Metabolex

  • Attractiveness of PPAR-gamma insulin sensitizers in diabetes treatment
  • Need for second generation compounds with reduced side effects
  • Advantages of partial PPAR-gamma agonists
  • MBX-102: glucose and lipid lowering without edema
  • MBX-2044: newer analogs of MBX-102
  • 15:40 Afternoon Tea

    16:00 SYNDROME X

    Dr Jacques Mizrahi

    Dr Jacques Mizrahi, Director, Global Therapy Area Head, Vascular & Metabolic Diseases, F Hoffmann-La Roche

  • Diabetes, obesity, vascular and dyslipidemia contribution to the metabolic syndrome
  • Impact on cardiovascular diseases
  • Cluster of inter independent risk factors or distinct entity?
  • From where to start treating a metabolic syndrome patients?
  • 16:40 EXPLOITING THE PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR PLATFORM FOR TREATMENT OF THE METABOLIC SYNDROME

    Dr Mark Leibowitz

    Dr Mark Leibowitz, Director, Pharmacology, Ligand Pharmaceuticals

  • Introduction to the RXR:PPAR heterodimers
  • Insulin sensitization
  • Dyslipidemia and atherosclerosis
  • Combined activities
  • Alternative approaches and new opportunities
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Professor David Leslie

    Professor David Leslie, Professor, Diabetes & Autoimmunity, Queen Mary College, University of London

    9:10 GLP-1 ANALOGUES AND EXENATIDE

    Dr Michael Trautmann

    Dr Michael Trautmann, Medical Advisor, Eli Lilly

  • Overview of GLP-1 physiology and potential therapeutic application
  • An agent stimulating insulin production and secretion through activation of the GLP-1receptor
  • Multiple modes of action contribute to improved glycemic control
  • Effects on beta-cell preservation
  • Protection against rapid proteolytic breakdown
  • Current studies on effects on glycemic control and weight control
  • 9:40 PEPTIDERGIC CONTROL OF NUTRIENT ASSIMILATION AS A THERAPEUTIC MODE IN METABOLIC DISEASE

    Dr Andrew Young

    Dr Andrew Young, Vice President & Senior Research Fellow, Amylin

  • Role of nutrient appearance vs disappearance in fuel homeostasis
  • Points of control for nutrient appearance
  • Actions of pramlintide, exenatide and PYY[3-36]
  • Effects in animal models
  • Clinical data
  • 10:20 DPP IV INHIBITORS

    Dr Smilinia Ristic

    Dr Smilinia Ristic, Global Head, Diabetes Clinical Research, Novartis

  • Structure and expression of DPP IV
  • DPP IV inhibition in animal models of diabetes
  • Clinical efficacy and safety of DPP IV inhibitors
  • 11:00 Morning Coffee

    11:20 THERAPY FOR TYPE II DIABETES

    Rachel Mayers

    Rachel Mayers, Team Leader, CVGI Discovery, AstraZeneca

  • Discovery of novel inhibitors by functional screening
  • Isoform selectivity
  • Activation of PDH in vitro and in vivo
  • Effectiveness in animal disease models
  • 12:00 IMPACT OF CURRENT AND EMERGING THERAPIES ON DISEASE PROGRESSION

    Dr Janice Parker

    Dr Janice Parker, Principal Research Investigator, Pfizer

  • Current therapies for diabetes mellitus are designed to treat the symptoms of the disease and most have little impact on the progression from impaired glucose tolerance (IGT) or pre-diabetes to full-blown diabetes mellitus
  • Therapies that are disease modifying would offer obvious advantages in reducing progression from IGT to diabetes and ultimately to end-stage complications.
  • This presentation will review the activity of existing agents and evaluate the potential of novel emerging therapies, to modulate diabetes progression.
  • 12:40 Networking Lunch

    14:00 NEW INSIGHTS INTO SIGNALLING PATHWAYS IN METABOLISM AND INSULIN ACTION

    Prof Maria Paula Borges Macedo

    Prof Maria Paula Borges Macedo, Department of Physiology, Faculty of Medicine, New University of Lisbon

  • Hepatic control of peripheral insulin sensitivity
  • Hepatic glutathione, nitric oxide and insulin sensitivity
  • The role of the liver in animal models of insulin resistance
  • 14:40 EMERGING NON-INJECTABLE PROTEIN DRUGS FOR DIABETES

    Dr Christopher Price

    Dr Christopher Price, President & Chief Executive Officer, Nobex

  • Protein drugs in development for diabetes
  • Convenience, compliance, clinical advantages of non-injectable products
  • The key challenges for success
  • The marketplace: competition, product pricing and reimbursement
  • 15:20 Afternoon Tea

    15:40 ORAL INSULIN: MORE THAN SIMPLY ELIMINATING INJECTION

    Dr Michael Goldberg

    Dr Michael Goldberg, Chairman & Chief Executive Officer, Emisphere Technologies

  • Oral insulin - replaces first phase insulin response
  • Oral insulin - targets the liver
  • Oral insulin - clinical data in type I and type II patients
  • 16:20 AERX PULMONARY INSULIN DELIVERY SYSTEM

    Richard Thompson

    Richard Thompson, President & Chief Executive Officer, Aradigm

  • Are inhalers as effective as injections?
  • Inhalers: a more expensive alternative?
  • Concerns about the long-term effects of an inhaler on people with respiratory problems
  • A drug especially for asthmatic patients
  • The problem: exhibition of less insulin absorption
  • Asthma patients require a greater intake of insulin to control blood glucose
    Results from the phase II programme
  • 17:00 Chairman's Closing Remarks & End of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.